A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Clinical trial NCT02185690 · COMPLETED
Trial details
- NCT number
- NCT02185690
- Sponsor
- University Health Network, Toronto
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-07
- Primary completion
- 2019-07-04
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.